NOX-100 for Preventing Hypotension During Hemodialysis

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the safety, tolerability and efficacy profile of NOX-100 to reduce intradialytic hypotension (IDH) in patients undergoing chronic hemodialysis (HD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medinox, Inc.
• Collaborator: Orient Europharma Co., Ltd.
• Treatments: Nitric Oxide

Criteria

Inclusion Criteria:

• Males or non-pregnant, non-lactating females 20-80 years of age

• Patients who are hemodialysis dependent with a history of end-stage renal disease (ESRD) for at least 3 months and need at least three HD sessions per week

• History of intradialytic hypotension defined by at least 4 episodes with a fall in SBP of > 20 mmHg within 30 days prior to signing the ICF. At least two of the episodes must have caused symptoms requiring an intervention

• No change in anti-hypertensive regimen for at least one month prior to enrollment/randomization

• Be willing to sign the Informed Consent Form

Exclusion Criteria:

• Subjects with adequate laboratory results at screening

• Subjects with major psychiatric illness

• Subjects with history of arrhythmia or severe congestive heart failure (New York Heart Association (NYHA) Class III and IV) within past 6 months, or those with hypoxic myocardium confirmed by EKG

• Subjects with history of cirrhosis

• Subjects with active infection disease defined as current treatment with anti-infection agent(s)

• Subjects who need to receive nitrate and nitrite medication(s) (such as nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate) for regular treatment

• Subjects who need to receive unstable dose of midodrine, etilefrine or amezinium treatment within 7 days prior to receive the study treatment.

• More than 14 drinks of alcohol per week

• Use of any investigational drug or participation in any drug study within 30 days prior to enrollment/randomization

• Any clinical condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk to participate in the study or confounds the ability to interpret data from the study as judged by the investigator